Quinisocaine; Quinisocain; Isochinol; Pruralgan; Quinoleine; Chinisocain; Histaderme; Prulantex; Pruralgin; UNII-772EN3BH6I; 2-(3-butylisoquinolin-1-yl)oxy-N,N-dimethylethanamine; 772EN3BH6I; ISOQUINOLINE, 3-BUTYL-1-(2-(DIMETHYLAMINO)ETHOXY)-; 3-Butyl-1-[2-(dimethylamino)ethoxy]isoquinoline; Chinisocainum; Ethanamine, 2-((3-butyl-1-isoquinolinyl)oxy)-N,N-dimethyl-; Ethanamine, 2-[(3-butyl-1-isoquinolinyl)oxy]-N,N-dimethyl-; [2-(3-butylisoquinolyloxy)ethyl]dimethylamine; Quinisocaina; Quinisocainum; Quinisocaine [INN:BAN]; Quinisocainum [INN-Latin]; Quinisocaina [INN-Spanish]; NCGC00016618-01; 3-Butyl-1-(2-dimethylaminoethoxy)isoquinoline; EINECS 201-700-0; Isoquinoline, 3-butyl-1-[2-(dimethylamino)ethoxy]-; BRN 0018179; quinolein; Kinisokain; 1-(2-Dimethylaminoethoxy)-3-butylisochinolin; N-{2-[(3-butyl-1-isoquinolinyl)oxy]ethyl}-N,N-dimethylamine; Quinisocaine (INN); 2-[(3-Butyl-1-isoquinolinyl)oxy]-N,N-dimethylethanamine; Prestwick0_000630; Prestwick1_000630; Prestwick2_000630; Prestwick3_000630; SCHEMBL8191; BSPBio_000600; 5-21-03-00414 (Beilstein Handbook Reference); SPBio_002819; BPBio1_000660; CHEMBL127643; DTXSID8048525; NSC39695; ZINC1671507; BDBM50225699; NSC-39695; AKOS022143560; DB13683; MCULE-8714132699; WLN: T66 CNJ BO2N1&1 D4; NCGC00016618-02; ST076784; 2-(Dimethylamino)ethoxy-3-butyl-isoquinoline; AB00514685; D08462; 3-Butyl-1-[2-(dimethylamino)ethyl]isoquinoline; AO-080/43342670; Isoquinoline, 3-butyl-1-[2-(dimethylamino)ethyl]-; Q1478199; 1-(.beta.-Dimethylaminoethoxy)-3-N-butylisoquinoline; BRD-K73391359-003-03-7; 2-[(3-Butyl-1-isoquinolinyl)oxy]-N,N-dimethylethanamine #